Sabalenka Backs WTA's New Genetic Sex Testing Policy, Sparking Wide Debate

Tennis World No. 1 Aryna Sabalenka has publicly endorsed the Women's Tennis Association's (WTA) new genetic sex testing policy, a significant shift in eligibility rules that began implementation in July 2026. Her support for the controversial measure comes as the sports world grapples with balancing fairness in women's categories with inclusivity, rekindling a long-standing debate about sex verification in athletics. The WTA's updated regulations, which require all players to undergo a one-time SRY gene test, aim to clarify eligibility criteria but have drawn both praise for safeguarding competitive balance and criticism for potential human rights implications.

The new WTA policy mandates that all players provide a cheek swab, blood, or saliva sample for genetic screening. The test specifically looks for the presence of the SRY gene, a segment of DNA located on the Y chromosome that plays a pivotal role in the development of male characteristics. Under these new rules, only players who test negative for the SRY gene will be permitted to compete on the WTA Tour. This marks a departure from the WTA's previous guidelines, which allowed transgender women to participate provided they identified as female and maintained testosterone levels below a specified threshold for at least two years. The move aligns with a similar stance taken by the International Olympic Committee (IOC), which announced in March 2026 that SRY gene screening would be a requirement for all women athletes competing in Olympic events starting with the LA28 Games.

Aryna Sabalenka, a prominent voice in women's tennis, articulated her firm support for the revised policy during a press conference ahead of the North American hard-court season. "I think it's really important to keep the fairness in our tour," Sabalenka stated. She further elaborated on her rationale, asserting, "It's obviously, biologically, the men are way stronger than women, so I feel like it would be not really fair for the woman to compete against biological men." Sabalenka expressed a willingness to comply with the new testing, adding, "If they want to test us all, I'm happy to do that; it's pretty fair, and let's keep it that way." Her comments underscore a perspective held by some athletes and organizations who believe that biological differences between sexes necessitate distinct competitive categories, and that genetic screening is a necessary measure to uphold the integrity of women's sports.

The reintroduction of genetic sex testing in elite sports, however, is not without historical precedent or significant controversy. Sex verification in athletics dates back to the 1940s, evolving from visual inspections and physical examinations to chromosomal and hormone level testing. Many of these practices were criticized for being invasive, unreliable, and often discriminatory, particularly against intersex athletes or women whose appearances did not conform to traditional feminine stereotypes. The IOC itself abandoned genetic sex testing around 2000 due to concerns about its scientific validity and the harm it inflicted on athletes. Critics of the new WTA and IOC policies highlight that relying solely on the SRY gene oversimplifies biological sex, which is a complex spectrum. They point out that individuals with Differences of Sex Development (DSD) may possess the SRY gene despite being identified and raised as female, effectively rendering them ineligible under the new rules. Past instances of sex verification have led to unjustified disqualification, severe psychological distress, social isolation, and even suicide among affected athletes.

Human rights advocates and several organizations have voiced strong opposition, arguing that mandatory genetic testing is an invasive breach of privacy and a potential violation of human rights. They contend that such policies disproportionately target women of color, intersex individuals, and transgender athletes, creating an environment of suspicion and exclusion rather than fostering true equality in sports. Furthermore, critics question the scientific basis for the policies, noting that many scientists argue there is no single gene or test that can definitively define sex in a clear or fair manner for athletic eligibility. These concerns also extend to the logistical and ethical challenges of storing sensitive medical data and ensuring informed consent from athletes, particularly minors.

While the WTA's new policy, supported by high-profile athletes like Sabalenka, aims to address competitive fairness, it rekindles a complex and deeply sensitive debate. The move has been praised by those who believe it protects the category of women's sports by acknowledging fundamental biological differences. Conversely, it faces intense scrutiny from those who view it as an oversimplification of human biology, discriminatory in practice, and a step backward for inclusivity and human rights in sports. The policy's full impact on the tennis landscape and the broader sporting community will continue to unfold as athletes, governing bodies, and advocacy groups navigate the implications of these new genetic verification requirements.